GT201500035A - ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS - Google Patents

ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS

Info

Publication number
GT201500035A
GT201500035A GT201500035A GT201500035A GT201500035A GT 201500035 A GT201500035 A GT 201500035A GT 201500035 A GT201500035 A GT 201500035A GT 201500035 A GT201500035 A GT 201500035A GT 201500035 A GT201500035 A GT 201500035A
Authority
GT
Guatemala
Prior art keywords
microspheres
pharmaceutical composition
oral pharmaceutical
elaboration process
composition
Prior art date
Application number
GT201500035A
Other languages
Spanish (es)
Inventor
Barranco Hernandez Gustavo
Del Coral Luna Guiza María
Senosiain Arroyo Héctor
Original Assignee
Laboratorios Senosiain S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50435594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201500035(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Senosiain S A De C V filed Critical Laboratorios Senosiain S A De C V
Publication of GT201500035A publication Critical patent/GT201500035A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN PARA ADMINISTRACIÓN ORAL EN FORMA DE MICROPARTÍCULAS, POR EJEMPLO MICROESFERAS O PELLETS, ASÍ COMO EL PROCESO PARA SU ELABORACIÓN. LA INVENCIÓN TAMBIÉN SE REFIERE A UNA COMPOSICIÓN QUE CONTIENE UN DIURÉTICO Y EL USO DE LA COMPOSICIÓN PARA EL TRATAMIENTO DE EDEMA, TRASTORNOS CARDIOVACULARES, HIPERTENSIÓN, DAÑO RENAL, DAÑO HEPÁTICO, ENTRE OTROS.THE PRESENT INVENTION REFERS TO A COMPOSITION FOR ORAL ADMINISTRATION IN THE FORM OF MICROPARTICLES, BY EXAMPLE MICROSPHERES OR PELLETS, AS WELL AS THE PROCESS FOR THEIR DEVELOPMENT. THE INVENTION ALSO REFERS TO A COMPOSITION CONTAINING A DIURETIC AND THE USE OF COMPOSITION FOR EDEMA TREATMENT, CARDIOVACULAR DISORDERS, HYPERTENSION, RENAL DAMAGE, HEART DAMAGE, BETWEEN OTHERS.

GT201500035A 2012-08-17 2015-02-16 ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS GT201500035A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012009583A MX351059B (en) 2012-08-17 2012-08-17 Oral pharmaceutical composition in the form of microspheres and preparation method.

Publications (1)

Publication Number Publication Date
GT201500035A true GT201500035A (en) 2017-10-24

Family

ID=50435594

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201500035A GT201500035A (en) 2012-08-17 2015-02-16 ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS

Country Status (8)

Country Link
CL (1) CL2015000375A1 (en)
CO (1) CO7310526A2 (en)
CR (1) CR20150077A (en)
DO (1) DOP2015000028A (en)
GT (1) GT201500035A (en)
MX (1) MX351059B (en)
PE (1) PE20150710A1 (en)
WO (1) WO2014027334A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2685269T3 (en) 2013-03-27 2018-10-08 F. Hoffmann-La Roche Ag Genetic markers to predict the degree of response to treatment
IL300472A (en) 2014-07-30 2023-04-01 Hoffmann La Roche Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
CN104523710B (en) * 2014-12-30 2018-05-25 石药集团欧意药业有限公司 A kind of bisulfate clopidogrel aspirin Composite Double synusia and preparation method thereof
KR101710441B1 (en) * 2015-12-28 2017-02-28 신풍제약주식회사 Tablet with improved stability and dissolution
WO2018150286A1 (en) 2017-02-17 2018-08-23 Unichem Laboratories Ltd Pharmaceutical composition of apixaban
CN106821996A (en) * 2017-03-01 2017-06-13 华益药业科技(安徽)有限公司 Enalapril maleate granule and preparation method thereof
JP7382957B2 (en) * 2018-04-16 2023-11-17 ブリストル－マイヤーズ スクイブ カンパニー Apixaban formulation
US20210290543A1 (en) * 2020-02-19 2021-09-23 Nano Pharmasolutions, Inc. Therapeutic agent nanoparticles and methods of preparation
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition
CN113413364A (en) * 2021-05-31 2021-09-21 辰欣药业股份有限公司 Enoxaparin sodium injection and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976486A1 (en) * 2006-01-27 2008-10-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
MXPA06010972A (en) * 2006-09-25 2009-04-17 World Trade Imp Export Wtie Ag Process for stabilizing famotidine.
WO2008045006A1 (en) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
MX2007008440A (en) * 2007-07-11 2009-02-18 Senosiain S A De C V Lab Combined pharmaceutical composition.

Also Published As

Publication number Publication date
PE20150710A1 (en) 2015-05-28
CO7310526A2 (en) 2015-06-30
DOP2015000028A (en) 2015-03-15
WO2014027334A2 (en) 2014-02-20
CR20150077A (en) 2015-05-13
MX351059B (en) 2017-09-29
MX2012009583A (en) 2014-02-26
CL2015000375A1 (en) 2015-07-10
WO2014027334A3 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
GT201500035A (en) ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS
PE20150631A1 (en) CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
CL2014001158A1 (en) Alkylated piperazine derivative compounds; pharmaceutical composition that includes them; process to prepare the pharmaceutical composition; kit and use in the treatment of immune disorders, cancer, cardiovascular diseases, inflammation, among others.
CL2015002164A1 (en) Combined formulation of two antiviral compounds.
BR112015020389A2 (en) carbazole compounds useful as bromodomain inhibitors
UY35590A (en) NEW COMPOUNDS FOR CANCER TREATMENT
CL2014002757A1 (en) Compounds derived from benzamide to inhibit the activity of abl1, abl2 and bcr-abl1, pharmaceutical composition; and use in the treatment of cancer.
CR20150326A (en) AUTOTAXIN INHIBITORS
ECSP14026138A (en) URACILOS REPLACED BICYCLICALLY AND USE OF THE SAME
TR201902516T4 (en) Glucagon-glp-1-envy triple agonist compounds.
CO6771417A2 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
EA201692301A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
MX2015008627A (en) Boronic acid derivatives and therapeutic uses thereof.
MX365939B (en) Nuclear transport modulators and uses thereof.
UY34918A (en) New 5-aminotetrahydroquinolin-2-carboxylic acids and their use
UY33396A (en) 5-FLUORO-1H-REPLACED PIRAZOLOPIRIDINES AND ITS USE
EA201591404A1 (en) SPIROLACTAM NMDA RECEPTOR MODULATORS AND THEIR APPLICATION
CL2013002650A1 (en) Tricyclic derivative compounds with activity on nuclear hormone receptors; pharmaceutical composition that includes them; intermediate compound repair process; and use in the treatment of AIDS, acute adrenal insufficiency, addison's disease, allergic rhinitis, Alzheimer's disease, among others.
UY35276A (en) New compounds that inhibit the activity of Lp-PLA2
CL2015001610A1 (en) Compounds derived from pyrimido- [4,5-b] -quinoline-4,5 (3h, 10h) -diones to be used as a medicament for the treatment of a disease caused by a nonsense mutation; composition and pharmaceutical combination that includes them.
MX2016003823A (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma.
MX367926B (en) Pharmaceutical composition for a sustained release of lanreotide.
CL2013003700A1 (en) Topical ophthalmological pharmaceutical composition comprising regorafenib, which is suspended in a pharmaceutically acceptable vehicle; manufacturing procedure and its use to treat or prevent an ophthalmological disorder.
GT201300304A (en) 1-PIPERAZINO-3-PHENYL-INDANOS DEUTERATED FOR THE TREATMENT OF SCHIZOPHRENIA
UY34931A (en) ? COMPOSITE FORMULATION FOR ORAL ADMINISTRATION THAT INCLUDES METFORMIN AND ROSUVASTATIN ?.